CVAC

CureVac N.V. (CVAC) | Rumor.io

CureVac

CVAC

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CVAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Aug 8

CureVac (CVAC) has resolved its patent litigation with BioNTech (BNTX) ahead of a potential buyout deal.
CureVac will receive $740 million and royalties from BioNTech as part of the agreement.
The resolution of the patent fight is seen as a positive development for CureVac ahead of a potential buyout.

Generated by AI

Sentiment

Of the messages about CVAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100%	96.19% +12.51
Bearish	0% 0	0%	0%	3.81% -12.51

Bullish· Jun 12

CVAC is attractive due to a merger premium and the biotech boom, with a strong pipeline including cancer, glioblastoma, and UTI vaccine trials.
The company has no funding worries with €438m in cash, and patent wins and IND approvals provide IP and R&D momentum.
The acquisition by BioNTech at a 55% premium provides a significant gain for shareholders, with the highest share price since December 2023.

Bearish· Dec 19

The German court invalidated CureVac's mRNA technology patent, challenged by BioNTech, weakening its patent portfolio and mRNA development.
CureVac's stock price plummeted 40% in premarket session and is now oversold, with a market cap sustained by false hope and no commercial product or revenue.
The company's patent portfolio and mRNA development have been significantly impacted, potentially leading to a commercial product and revenue shortfall, and the stock may tank further due to tax losses.

Generated by AI

Topics

Of the messages about CVAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.23%
Announcements	—	—	—	87.82%
Controversies	—	—	—	4.6%
Earnings	—	—	—	0.23%
Macro	—	—	—	0%
Technical Analysis	—	—	—	7.13%

Analysts· Jan 21

BofA Securities downgraded CureVac (CVAC) to Underperform from Neutral and lowered the price target to $20 from $55.
The downgrade was due to limited catalyst flow in 2022, with BofA Securities analyst Geoff Meacham citing minimal COVID-19 upside.
CureVac's stock price declined by 14% to $18.73 following the downgrade.

Announcements· Jun 12

BioNTech has agreed to acquire CureVac in an all-stock transaction valued at approximately $1.25 billion, with each CureVac share being exchanged for around $5.46 in BioNTech ADSs.
The acquisition will bring together two complementary companies, with CureVac's mRNA-based cancer immunotherapy efforts being integrated into BioNTech's existing position in the global mRNA industry.
The deal offers CureVac shareholders a 55% premium and values the company at $1.25 billion, with the transaction expected to close in 2025 and CureVac shareholders expected to own between 4% and 6% of BioNTech.

Controversies· Dec 19

A German court invalidated CureVac's patent, which was the basis of a patent violation lawsuit against BioNTech, potentially weakening CureVac's patent portfolio and mRNA development.
The court's decision was seen as a blow to CureVac's claims for a share in billions of dollars in COVID-19 vaccine revenues.
CureVac's stock price declined around 15% after the court's decision, with the company's shares hitting an all-time low.

Technical Analysis· Jun 18

$CVAC has potential to fill the gap and move back up to $68 resistance, with a possible target of $80 if momentum is caught.
The stock's technicals are strong, with a 50% retracement fib at $72, and a possible squeeze to head up into the next level.
$CVAC's price has fallen below its 50-day Moving Average, but the author is raising their price targets higher, expecting the stock to triple digits again.

Generated by AI

Community

Of the messages about CVAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	51.57%
Newcomers	100%	100%	100%	48.43%

Regulars· Jun 12

Evercore ISI believes the $BNTX $CVAC deal is primarily about avoiding litigation, with little value attributed to CureVac's pipeline.
BioNTech's acquisition of CureVac for $1.25 billion represents a 55% premium, and CureVac will own 4-6% of BioNTech.
The acquisition will boost BioNTech's mRNA pipeline, lift stocks, and end lawsuits between the two companies.

Newcomers· Jun 23

New investors are bullish on CVAC, expecting it to take off ($CVAC).
CVAC's performance is being compared to other symbols in a list ($CVAC).
The post "Here we go" is being used to express enthusiasm for CVAC, with a chart symbol and arrow.

Generated by AI

News

Moderna says CureVac broke agreement by suing over COVID vaccine patents

2mo agoReuters

Moderna counters CureVac patent lawsuit over Covid-19 vaccines

2mo agoInvesting.com

Also Discussed

Investors talking about CVAC also mention

#	Name	Attention
1	BioNTech SEBNTX	0%+0
2	Valneva SE Sponsored ADRVALN	0%new
3	TBIO - Telesis Bio, Inc.	——
4	Moderna Inc.MRNA	0.1%+0.03
5	Vir Biotechnology, Inc.VIR	0%+0
6	Novavax Inc.NVAX	0.06%+0.01
7	Banco BBVA Argentina S.A. ADRBBAR	0%new
8	Immunocore Holdings plc ADRIMCR	0%0
9	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
10	GRTS - Gritstone bio, Inc.	——

CureVac N.V.

Location

Social

What share of all stock conversation is about CVAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Aug 8

CureVac (CVAC) has resolved its patent litigation with BioNTech (BNTX) ahead of a potential buyout deal.
CureVac will receive $740 million and royalties from BioNTech as part of the agreement.
The resolution of the patent fight is seen as a positive development for CureVac ahead of a potential buyout.

Generated by AI

Sentiment

Of the messages about CVAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100%	96.19% +12.51
Bearish	0% 0	0%	0%	3.81% -12.51

Bullish· Jun 12

CVAC is attractive due to a merger premium and the biotech boom, with a strong pipeline including cancer, glioblastoma, and UTI vaccine trials.
The company has no funding worries with €438m in cash, and patent wins and IND approvals provide IP and R&D momentum.
The acquisition by BioNTech at a 55% premium provides a significant gain for shareholders, with the highest share price since December 2023.

Bearish· Dec 19

The German court invalidated CureVac's mRNA technology patent, challenged by BioNTech, weakening its patent portfolio and mRNA development.
CureVac's stock price plummeted 40% in premarket session and is now oversold, with a market cap sustained by false hope and no commercial product or revenue.
The company's patent portfolio and mRNA development have been significantly impacted, potentially leading to a commercial product and revenue shortfall, and the stock may tank further due to tax losses.

Generated by AI

Topics

Of the messages about CVAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.23%
Announcements	—	—	—	87.82%
Controversies	—	—	—	4.6%
Earnings	—	—	—	0.23%
Macro	—	—	—	0%
Technical Analysis	—	—	—	7.13%

Analysts· Jan 21

BofA Securities downgraded CureVac (CVAC) to Underperform from Neutral and lowered the price target to $20 from $55.
The downgrade was due to limited catalyst flow in 2022, with BofA Securities analyst Geoff Meacham citing minimal COVID-19 upside.
CureVac's stock price declined by 14% to $18.73 following the downgrade.

Announcements· Jun 12

BioNTech has agreed to acquire CureVac in an all-stock transaction valued at approximately $1.25 billion, with each CureVac share being exchanged for around $5.46 in BioNTech ADSs.
The acquisition will bring together two complementary companies, with CureVac's mRNA-based cancer immunotherapy efforts being integrated into BioNTech's existing position in the global mRNA industry.
The deal offers CureVac shareholders a 55% premium and values the company at $1.25 billion, with the transaction expected to close in 2025 and CureVac shareholders expected to own between 4% and 6% of BioNTech.

Controversies· Dec 19

A German court invalidated CureVac's patent, which was the basis of a patent violation lawsuit against BioNTech, potentially weakening CureVac's patent portfolio and mRNA development.
The court's decision was seen as a blow to CureVac's claims for a share in billions of dollars in COVID-19 vaccine revenues.
CureVac's stock price declined around 15% after the court's decision, with the company's shares hitting an all-time low.

Technical Analysis· Jun 18

$CVAC has potential to fill the gap and move back up to $68 resistance, with a possible target of $80 if momentum is caught.
The stock's technicals are strong, with a 50% retracement fib at $72, and a possible squeeze to head up into the next level.
$CVAC's price has fallen below its 50-day Moving Average, but the author is raising their price targets higher, expecting the stock to triple digits again.

Generated by AI

Community

Of the messages about CVAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	51.57%
Newcomers	100%	100%	100%	48.43%

Regulars· Jun 12

Evercore ISI believes the $BNTX $CVAC deal is primarily about avoiding litigation, with little value attributed to CureVac's pipeline.
BioNTech's acquisition of CureVac for $1.25 billion represents a 55% premium, and CureVac will own 4-6% of BioNTech.
The acquisition will boost BioNTech's mRNA pipeline, lift stocks, and end lawsuits between the two companies.

Newcomers· Jun 23

New investors are bullish on CVAC, expecting it to take off ($CVAC).
CVAC's performance is being compared to other symbols in a list ($CVAC).
The post "Here we go" is being used to express enthusiasm for CVAC, with a chart symbol and arrow.

Generated by AI

CureVac

Social

Aug 8

Bullish· Jun 12

Bearish· Dec 19

Analysts· Jan 21

Announcements· Jun 12

Controversies· Dec 19

Technical Analysis· Jun 18

Regulars· Jun 12

Newcomers· Jun 23

Moderna says CureVac broke agreement by suing over COVID vaccine patents

Moderna counters CureVac patent lawsuit over Covid-19 vaccines

Also Discussed

CureVac N.V.

Company Information

Location

Moderna says CureVac broke agreement by suing over COVID vaccine patents

Moderna counters CureVac patent lawsuit over Covid-19 vaccines

Also Discussed

Social

Aug 8

Bullish· Jun 12

Bearish· Dec 19

Analysts· Jan 21

Announcements· Jun 12

Controversies· Dec 19

Technical Analysis· Jun 18

Regulars· Jun 12

Newcomers· Jun 23